Business
Jazz Pharmaceuticals Announces Third Quarter 2020 Financial Results
Strong Financial and Operational Performance in Third Quarter 2020 Total Revenues Increased 12% Compared to Third Quarter 2019 Strong Demand for Zepzelca
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"Strong Financial and Operational Performance in Third Quarter 2020\n Total Revenues Increased 12% Compared to Third Quarter 2019\n Strong Demand for Zepzelca Following July Launch\n Launched Xywav for Narcolepsy in the U.S.\n Announced Clinically Meaningful Phase 3 Top-Line Results for JZP-258 in Idiopathic Hypersomnia\n 2020 Total Revenue Guidance Increased to a Range of $2.32 Billion to $2.38 Billion\n\n\nDUBLIN, Nov. 2, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2020 and updated its 2020 financial guidance.\n\"We delivered strong financial results this quarter, with increasingly diversified revenues fueled by the recent launch of Zepzelca, an innovative new treatment for relapsed small cell lung cancer, which we expect to be a catalyst for significant growth in our oncology portfolio. During 2020, we are demonstrating our operational agility as we navigate through the COVID-19 pandemic and deliver on a set of critically important objectives,\" said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. \"This is a transformative year for Jazz and today marks our third product launch in 2020, keeping us on track to execute up to five key launches through 2020 and 2021. We continue to build upon our strong foundation by investing in assets to further diversify and expand our innovative neuroscience and oncology pipelines. We are excited about the opportunities ahead to deliver life-changing therapies for patients and drive enhanced shareholder value.\"\nRobert Iannone, M.D., M.S.C.E., executive vice president, research and development, of Jazz Pharmaceuticals added, \"We achieved multiple key R&D objectives in the third quarter, highlighted by FDA approval of Xywav in narcolepsy. We are encouraged by compelling top-line data for JZP-258 in idiopathic hypersomnia and are preparing to submit our supplemental NDA in the first quarter of 2021. With the significant progress and successes in our regulatory and R&D operations this year, we are poised to bring multiple new and highly differentiated treatment options to patients in areas of high unmet medical need.\" \nThe company successfully executed on multiple prioritized objectives for 2020 across its business, including commercial, regulatory and R&D operations, despite the COVID-19 p...